Abstract:Abstract Background: Addition of taxanes to adjuvant chemotherapy provides survival benefit in patients with early breast cancer (EBC). Intensifying adjuvant regimens with taxanes leads to increased toxicity, including higher rates of sensory peripheral neuropathy (sPN). Prevalence of chemotherapy induced peripheral neuropathy (CIPN) in trials varies with reported rates of 15 - 30%. Up to 15% of patients report persistent CIPN 1-3 years post treatment with associated adverse impact on quality of life (QOL). There is limited data reporting rates of CIPN and QOL beyond 3 years. We assessed rates of persistent sPN in real world patients with EBC treated with adjuvant taxanes and its effect on QOL. Methods: Patients who received adjuvant taxane for EBC at a metropolitan health service in the preceding 10 years were identified from hospital records and invited to participate. Data was collected at a single time point using the EORTC Quality of Life (QLQ30) and Chemotherapy-Induced Peripheral Neuropathy (CIPN20) questionnaires. Demographic, co-morbid and treatment details were collected from medical records. Raw scores were linearly transformed to a 0 to 100 scale with higher scores indicating higher functioning, QOL and levels of symptomatology. Prevalence was determined using a binary model of no or any sPN and cases grouped into no/mild or moderate/severe for further analysis. Groupwise comparisons were performed with parametric and non-parametric tests. Analysis of covariance was used to fit models incorporating comorbid factors such as diabetes with time point of assessment as the covariate. Results: 176 of 250 questionnaires were returned, a response rate of 71%. Median age was 59 (range 30-88 years) with 52% of respondents receiving paclitaxel vs 47% docetaxel containing regimens. Median time from completion of taxane was 30 months (range 6-120 months). 11 patients (6%) had known diabetes and 50 (26%) had at least one other known risk factor for neuropathy. The prevalence of CIPN across all time points was 74.4%, much higher than seen in historical trials. Table 1: Incidence of sensory neuropathy (all grades) by time from chemotherapyTime bracket (months)N= (176)PN (%)No PN (%)6-246352 (82.5)11 (17.5)25-486347 (74.6)16 (25.4)49-1205032 (64%)18 (36%) QOL scores were lower in patients with moderate/severe sPN, with a median global QOL scaled score of 50 vs 75 in patient with no/mild sPN (p = 0.0062). Increasing sPN score was associated with lower QOL score controlling for time from chemotherapy (standardised beta co-efficient -0.28). In an analysis of covariance, diabetes was the only significant comorbid factor associated with higher sPN scores. In the final model incorporating diabetes, miscellaneous other sPN risk factors and time from chemotherapy, diabetes was associated with increased sPN scores with a small effect size (p = 0.03). Paclitaxel was associated with higher sPN scores than docetaxel (p 0.0001) with significant interaction of paclitaxel with diabetes independent of other sPN risk factors and time from chemotherapy (p = 0.02). Paclitaxel was associated with higher sPN scores in diabetic patients (adjusted mean score in diabetic patients 46.7 v 20.9 in non-diabetic receiving paclitaxel, p = 0.001). Conclusion: CIPN is significantly more prevalent in this real world cohort than reported in historic data, with persistent sPN having a negative correlation with QOL out to 10 years. Higher rates of paclitaxel-associated sPN in diabetic patients could inform decision making on adjuvant chemotherapy. Citation Format: Elizabeth F Blackley, Megan G Kesper, Peter Savas, Bianca Devitt. Long-term incidence of taxane induced peripheral neuropathy in early breast cancer patients, a real world, single centre experience exploring effects on health related quality of life [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-17-06.

The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial

Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer

Everyday life with long-term chemotherapy induced peripheral neuropathy among patient in adjuvant treatment for colorectal cancer: A multi methods study

Chemotherapy-Induced Neutropenia As a Prognostic Factor in Patients with Advanced Epithelial Ovarian Carcinoma

Identifying patient characteristics associated with chemotherapy-induced peripheral neuropathy (CIPN) severity in a phase II clinical trial: A retrospective analysis.

The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients

Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy

Peripheral Neuropathy in Cancer Patients- Multifactorial Contributors to Dose Limiting and Chronic Toxicity

Dietary quality and chemotherapy‐induced peripheral neuropathy in colon cancer

Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis

Correlates of Taxane-Induced Neuropathy, an Electronic Health Record Based Observational Study

Abstract P1-17-06: Long-term incidence of taxane induced peripheral neuropathy in early breast cancer patients, a real world, single centre experience exploring effects on health related quality of life

NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN)

Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort

Is CT-based body composition associated with long-term chemotherapy-induced peripheral neuropathy in colorectal cancer survivors?

Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study

Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer

Chemotherapy-induced peripheral neuropathy: where are we now?

Clinical and Electrophysiological Studies of Chemotherapy-induced Peripheral Neuropathy

Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study

Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life